Letter to the Editor| Volume 130, P269-271, May 2020

Download started.


Atypical extended immune-related neutropenia in patient treated with pembrolizumab

Published:March 17, 2020DOI:
      Immune checkpoint inhibitors are revolutionizing cancer treatment for many patients, alongside surgery, chemotherapy and radiotherapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Scotté F.
        • Ratta R.
        • Beuzeboc P.
        Side effects of immunotherapy: a constant challenge for oncologists.
        Curr Opin Oncol. 2019; 31: 280-285
        • Trinh S.
        • Le A.
        • Gowani S.
        • La-Beck N.M.
        Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines.
        Asia Pac J Oncol Nurs. 2019 Apr-Jun; 6: 154-160
        • Kean L.S.
        • Turka L.A.
        • Blazar B.R.
        Advances in targeting Co-inhibitory and Co-stimulatory pathways in transplantation settings: the yin to the yang of cancer immunotherapy.
        Immunol Rev. 2017 Mar; 276: 192-212
        • Michot J.M.
        • Lazarovici J.
        • Tieu A.
        • Champiat S.
        • Voisin A.L.
        • Ebbo M.
        • et al.
        Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?.
        Eur J Canc. 2019 Nov; 122: 72-901
        • Wei Guoqing
        • Nwakuche Uzoma
        • Cadavid Gustavo
        • Ajaz Asim
        • Seiter Karen
        • Liu Delong
        Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma.
        Exp Hematol Oncol. Published online. 2012 Mar 26; 1: 3
        • Turgeman I.
        • Wollner M.
        • Hassoun G.
        • Bonstein L.
        • Bar-Sela G.
        Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.
        Anti Canc Drugs. 2017 Aug; 28: 811-814
        • Ban-Hoefen Makiko
        • Burack Richard
        • Lynn Sievert
        • Sahasrabudhe Deepak
        Ipilimumab-induced neutropenia in melanoma.
        J Investig Med High Impact Case Rep. 2016 Jul-Sep; 42324709616661835
        • Woźniak S.
        • Mackiewicz-Wysocka M.
        • Krokowicz Ł.
        • Kwinta Ł.
        • Mackiewicz J.
        Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab – case report.
        Oncol Res Treat. 2015; 38: 105-108
        • Simeone E.
        • Grimaldi A.M.
        • Esposito A.
        • Curvietto M.
        • Palla M.
        • Paone M.
        • et al.
        Serious haematological toxicity during and after ipilimumab treatment: a case series.
        J Med Case Rep. 2014 Jul 1; 8: 240
        • Barbacki A.
        • Maliha P.G.
        • Hudson M.
        • Small D.
        A case of severe Pembrolizumab-induced neutropenia.
        Anti Canc Drugs. 2018 Sep; 29: 817-819